This study is for adults with Large B-cell Lymphoma (LBCL) who have finished their first treatment and still have a small amount of cancer cells, called minimal residual disease (MRD). You would have completed standard first-line therapy (like R-CHOP) and have MRD detected by a special test. The study is testing a new cell therapy called cemacabtagene ansegedleucel (cema-cel), which is a type of CAR T-cell therapy. This therapy uses your own immune cells to fight cancer. Researchers want to see if cema-cel, given after a short chemotherapy (fludarabine and cyclophosphamide), is better than just watching to prevent the cancer from returning. The main goal is to see how long people live without their cancer coming back, for up to 60 months. The study plans to enroll 250 participants, but its current status is unclear.

Study design

This is a randomized, open-label study involving 250 participants. You would be randomly assigned to either receive cema-cel treatment or be in an observation group.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for up to 60 months to see how long they live without their cancer returning.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.